Product Description
Mechanisms of Action: PI3K Inhibitor,mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Verastem
Company Location: NEEDHAM MA 02494
Company CEO: Brian M. Stuglik
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lymphoma|Mesothelioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VS-5584-101 | P1 |
Terminated |
Lymphoma |
2016-12-01 |
|
| VS-6063-104 | P1 |
Terminated |
Mesothelioma |
2015-10-01 |